Controls and Procedures
+Added: Limitations on Effectiveness of Controls and Procedures
+Added: In designing and evaluating our disclosure controls and procedures, management recognizes that any controls
+Added: and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the
+Added: desired control objectives.
+Added: In addition, the design of disclosure controls and procedures must reflect the fact that there
+Added: are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible
+Added: controls and procedures relative to their costs
Evaluation of Disclosure Controls and Procedures
−Removed: Our principal executive officer and principal financial officer have concluded, based on their evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Report, that our disclosure controls and procedures are effective to ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure and that such information is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.
+Added: Our principal executive officer and principal financial officer have concluded, based on their evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Report, that our disclosure controls and procedures are effective at a reasonable assurance level.
+Added: As permitted by related SEC staff interpretive guidance for newly acquired
+Added: businesses, the internal control over financial reporting of Smiths Medical was excluded from the evaluation of the
+Added: effectiveness of our disclosure controls and procedures as of June 30, 2022.
+Added: Smiths Medical, which we acquired in
+Added: January 2022, represented approximately 41% of our consolidated total assets as of June 30, 2022, and 40% and 40%
+Added: of our consolidated total revenue for the three and six months ended June 30, 2022, respectively.
Changes in Internal Control Over Financial Reporting
−Removed: On January 6, 2022, we completed our acquisition of Smiths Medical and we continue to integrate the acquired operations.
−Removed: As the acquisition occurred in the first quarter of 2022, the scope of our evaluation of the effectiveness of internal control over financial reporting does not include Smiths Medical.
−Removed: This exclusion is in accordance with the SEC's general guidance that an assessment of a recently acquired business may be omitted from our scope for a period not to exceed one year from the date of the acquisition.
−Removed: There was no change in our internal control over financial reporting during the quarter ended March 31, 2022 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting, except as mentioned above.
+Added: There was no change in our internal control over financial reporting during the quarter ended June 30, 2022 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting, except as mentioned above.
PART II - OTHER INFORMATION
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.